His adrenal glands had been suppressed for so long they couldn't restart
Medicine sometimes offers tools designed for the short term that, when circumstances demand otherwise, reveal their limits over time. In the case of an 80-year-old man treated for years with metyrapone to manage Cushing's disease, the drug that suppressed a dangerous hormonal excess ultimately left his adrenal glands unable to recover — even after the pituitary tumor driving the condition was surgically removed. His story, published in AACE Endocrinology and Diabetes, is a quiet reminder that the body's endocrine architecture is both resilient and fragile, and that the interventions we use to protect it can, under prolonged pressure, reshape it in ways we did not intend.
- A man whose diabetes suddenly spiraled out of control was found to be carrying a hidden hormonal disorder — Cushing's disease — that had gone undetected for years while his body quietly changed around him.
- Diagnostic tests pointed in conflicting directions for four years, leaving clinicians without a clear surgical target and forcing them to rely on metyrapone as an extended holding measure rather than the brief bridge it was designed to be.
- When surgery finally succeeded in removing the pituitary tumor, the expected hormonal recovery never came — cortisol levels remained undetectable for more than a year, revealing that the drug had suppressed adrenal function far beyond the tumor's influence.
- The patient now requires ongoing hormone replacement therapy, and his case has become a clinical warning: prolonged metyrapone use can cause adrenocortical dysfunction that outlasts both the drug and the disease it was meant to control.
An 80-year-old man came to the hospital with uncontrolled diabetes, but the real story was written across his body — a rounded face, fat pooled at the base of his neck, thin skin marked with purple stretch marks. These were the signs of Cushing's disease, a condition of chronic cortisol excess driven by a tumor in the pituitary gland. Blood tests confirmed dangerously elevated ACTH and cortisol, but imaging found nothing. No tumor was visible anywhere.
Without a surgical target, physicians prescribed metyrapone — a drug that blocks cortisol production — as a temporary measure while the search continued. Months became years. A thyroid tumor appeared and was treated. ACTH levels kept climbing. It was not until four years into treatment, when a more aggressive suppression test finally produced the expected response, that the pituitary was confirmed as the source. Invasive sampling of the veins draining the gland sealed the diagnosis, and surgery was scheduled.
The operation succeeded. Surgeons removed a small pituitary tumor through the nose, and the hormonal markers of Cushing's disease began to fall. Blood sugar improved. The physical features started to ease. But when metyrapone and its companion replacement therapy were withdrawn, the adrenal glands did not wake up. Nine months after surgery, cortisol was still critically low. A year out, it remained undetectable.
The four years of metyrapone — a drug designed to suppress cortisol temporarily — had left the adrenal system unable to recover on its own, even after the tumor was gone and the drug was stopped. The case, now published in a peer-reviewed journal, carries a clear message for clinicians: extended metyrapone therapy can cause lasting adrenocortical dysfunction, and patients who receive it long-term must be monitored carefully, supported with hormone replacement, and prepared for a recovery that may take far longer than expected — or may never fully arrive.
An 80-year-old man arrived at the hospital in the spring of his life needing insulin for diabetes that had spiraled out of control. For three decades he had managed the condition through diet alone, but something had shifted. His blood pressure was elevated. His face had taken on a rounded appearance. Fat had accumulated between his shoulder blades. His skin had grown thin and fragile, marked with purple stretch marks that bruised easily. These were not the signs of simple diabetes. They were the unmistakable features of Cushing's disease.
The diagnostic puzzle began immediately. Blood tests showed dangerously high levels of ACTH and cortisol, the hormones that regulate stress response and metabolism. Standard suppression tests—the dexamethasone challenge, the corticotropin-releasing hormone stimulation—failed to produce the expected responses. The clinical picture pointed toward ectopic Cushing's, a rare variant where ACTH-producing tumors grow outside the pituitary gland, typically in the adrenal glands or elsewhere in the body. Imaging studies were ordered. Nothing appeared on the scans. No tumors in the adrenals. No lesions in the pituitary. The diagnosis remained elusive.
Without a clear surgical target, the physicians turned to metyrapone, a medication that blocks cortisol production. It is not a cure—it is a bridge, a way to lower hormone levels while the underlying cause is identified, or when surgery is not immediately possible. The man began the drug, and hydrocortisone replacement therapy was started to prevent his cortisol from dropping too low. Two years passed. His cortisol levels remained suppressed. Three years into treatment, he developed a thyroid tumor, which was surgically removed and treated with radiation. Still, his ACTH levels climbed.
Four years after starting metyrapone, a different test finally broke through. High-dose dexamethasone suppression, applied more aggressively, caused his ACTH and cortisol to fall—a response that indicated Cushing's disease, not ectopic Cushing's. Inferior petrosal sinus sampling, an invasive procedure measuring ACTH in the veins draining the pituitary gland, confirmed it: the pituitary was the source. A transsphenoidal surgery was scheduled—a minimally invasive approach through the nose to reach and remove the tumor. During the operation, surgeons found and removed a small pituitary tumor. His ACTH and cortisol levels dropped. The Cushing's features began to ease. His blood sugar improved.
But the story did not end with surgical success. Metyrapone and hydrocortisone were stopped. Dexamethasone was started to prevent adrenal insufficiency. Nine months after surgery, his cortisol levels were still dangerously low. The dexamethasone was switched to hydrocortisone. Four months later, his cortisol remained undetectable. A year after the operation that removed the tumor, his adrenal glands still were not producing cortisol on their own. The prolonged use of metyrapone—four years of a medication designed to suppress cortisol—had left his adrenal system unable to recover, even after the underlying tumor was gone and the drug was withdrawn.
The case, published in the journal AACE Endocrinology and Diabetes, represents a cautionary finding for clinicians. Metyrapone is meant to be a temporary tool, a way to manage Cushing's disease when surgery is delayed or impossible. But this man's experience shows that extended use can cause lasting damage to adrenal function. His cortisol remained undetectable for more than a year despite aggressive attempts to restore it. The researchers who documented his case emphasized a critical point: physicians must recognize that long-term metyrapone therapy can cause prolonged adrenocortical dysfunction that persists even after the drug is stopped and the tumor is removed. They must monitor these patients carefully, ensure appropriate hormone replacement, and understand that recovery may take far longer than expected—or may not come at all.
Citas Notables
Long-term metyrapone therapy can cause prolonged adrenocortical dysfunction after withdrawal— Researchers documenting the case
Clinicians should be aware of this potential complication and ensure appropriate glucocorticoid replacement and careful long-term monitoring— Study authors
La Conversación del Hearth Otra perspectiva de la historia
Why did it take four years to diagnose what was actually wrong with this man?
The initial imaging simply didn't show the pituitary tumor. It was small enough to hide. The clinical picture looked like ectopic Cushing's—tumors elsewhere—so they started metyrapone as a holding action while they searched. But the search took time, and the drug kept working, suppressing cortisol month after month.
So metyrapone was supposed to be temporary.
Yes. It's a bridge therapy. You use it to buy time until you can do surgery, or when surgery isn't an option. The problem here is that four years is not temporary. His adrenal glands essentially went to sleep under the medication's influence, and they didn't wake up when he stopped taking it.
Even after they removed the tumor?
Even after. That's the striking part. The surgery worked—his ACTH and cortisol dropped, the Cushing's features eased. But his adrenal glands had been suppressed for so long they couldn't restart on their own. A year later, his cortisol was still undetectable.
What does that mean for him practically?
It means he needs hormone replacement for the foreseeable future. His body can't produce cortisol naturally anymore. He's dependent on external glucocorticoids to survive. At 80, that's a significant burden.
Is this common?
The case report suggests it's not well-recognized. That's why the researchers published it—to alert other doctors that this can happen. If you're going to use metyrapone long-term, you need to know your patient might not recover normal adrenal function even after the underlying disease is treated.
What should doctors do differently?
Monitor more carefully. Don't assume recovery will happen just because you've removed the tumor and stopped the drug. Watch cortisol levels closely. Be prepared for the possibility that replacement therapy might be permanent.